市場調查報告書
商品編碼
1004982
卡斯爾曼氏病治療的全球市場 - 2022-2029Global Castleman Disease Treatment Market - 2022-2029 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
研究機構進行的卡斯爾曼病治療臨床試驗預計將推動市場增長。
卡斯爾曼氏病協作網絡 (CDCN) 與賓夕法尼亞大學和阿肯色大學醫學院合作,與研究藥物西羅莫司合作,用於治療對抗 IL 無反應的特發性多中心 卡斯爾曼氏病 (iMCD) 成人-6 療法。正在進行測試。西妥昔單抗 (Silvant) 和托珠單抗是兩種抗 IL-6 藥物 (Actemra)。此外,中國北京的北京協和醫院正在招募參與者進行一項臨床試驗,以測試硼替佐米、環磷□胺和地塞米松(BCD 方案)的有效性和安全性。因此,上述聲明預計將在預測期內推動市場。
由於該疾病的低流行率和對該疾病的了解不足,人們的意識低下。在預測期內,預計幾家公司的治療成本上升和專利到期將阻礙市場。
COVID-19 影響分析
COVID-19 大流行對醫療保健系統和市場產生了適度影響。 siltoximab 和 tocilizumab 等抗 IL6 藥物也用於治療一些危重患者的 COVID-19 誘導的細胞因子風暴。此外,siltoximab 和 tocilizumab 等抗 IL6 藥物現已被確定為一些特發性多中心 卡斯爾曼氏病患者的有效治療方法。這些藥物可以短期緩解症狀,但也很安全,可以長期控制那些有反應的人。在 COVID-19 大流行期間,CDCN 了解 siltoximab 和 tocilizumab 的短缺情況。 CDCN 擔心這些重要藥物對 卡斯爾曼氏病患者的可用性。 CDCN獲悉,siltoximab和tocilizumab的生產商已承諾為卡斯爾曼氏病患者提供藥物。因此,許多公司轉移到其他地區以確保產品可用性並保護其供應鏈。這樣一來,市場受到了影響,但隨著經濟活動的恢復,預計將獲得動力。
全球城堡疾病治療市場報告提供大約 45 多個市場數據表、40 多個數字和 180 頁內容。
The Global Castleman Disease Treatment Market is expected to grow at a high CAGR during the forecasting period (2022-2029).
Castleman disease is a rare disorder in which cells in the lymph nodes grow out of control. The most prevalent form of the disorder (unicentric Castleman disease) involves a single lymph node in the chest or belly. Depending on the patient's type of Castleman disease, treatment and prognosis will differ. Surgery is frequently successful in treating the type that involves only one lymph node.
Clinical trials conducted by the research institutes for the treatment of Castleman Disease are expected to drive market growth.
The Castleman Disease Collaborative Network (CDCN) has teamed up with the University of Pennsylvania and the University of Arkansas for Medical Sciences to conduct a study of sirolimus, an investigational medicine, for adults with idiopathic multicentric Castleman disease (iMCD) who have failed to respond to anti-IL-6 therapies. Siltuximab (Sylvant) and tocilizumab are two anti-IL-6 drugs (Actemra). Moreover, The Peking Union Medical College Hospital in Beijing, China, sought participants for a clinical trial examining the efficacy and safety of the drugs bortezomib, cyclophosphamide, and dexamethasone (BCD regimen). Thus, the market is expected to drive in the forecast period from the above statements.
Due to the disease's low prevalence rate and a lack of knowledge about it, there is a lack of awareness. The Patent expiry of several companies associated with the high cost of treatment are factors the market is expected to hamper in the forecast period.
COVID-19 Impact Analysis
The COVID-19 pandemic has moderately impacted healthcare systems and the market. Anti-IL6 drugs like siltuximab and tocilizumab are also being used to treat COVID-19-induced cytokine storms in some critically ill patients. Moreover, Anti-IL6 medicines like siltuximab and tocilizumab are now well-established as viable treatments for some individuals with idiopathic multicentric Castleman disease. These drugs alleviate symptoms in the short term, but they are also safe and provide long-term disease control in responders. During the COVID-19 pandemic, the CDCN understands a supply shortfall of siltuximab and tocilizumab. The CDCN is concerned about the availability of these important medications for Castleman Disease patients. The CDCN learned that the producers of siltuximab and tocilizumab are committed to providing the drugs to individuals with Castleman Disease. Therefore, many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.
Immunotherapy segment is expected to hold the largest market share in castleman disease treatment market
The immunotherapy segment is expected to dominate in 2021. The segment is benefitted because drugs like siltuximab (Sylvant) and rituximab (Rituxan) can inhibit the function of a protein that is overproduced in persons with multicentric Castleman disease. Moreover, medicines and other therapies to control cell overgrowth are commonly used to treat multicentric Castleman disease. Treatment options vary depending on the severity of your illness and whether the patient has HIV, HHV-8, or both. Therefore, these agents do not only control symptoms short-term but continued administration to responders is safe and provides durable disease control. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.
North America region holds the largest market share in the global castleman disease treatment market
In 2021, North America accounted for the highest revenue share. The increasing prevalence of idiopathic multicentric Castleman disease (iMCD), well-established infrastructure, companies focusing on research & development and performing clinical trials and the presence of major players as well as government measures that aid medicine development for orphan diseases are some of the factors the market is expected to boost in the forecast period. For instance, it is estimated that 6500 to 7700 new cases are diagnosed each year in the United States; approximately 1000 of those are HHV-8-associated multicentric Castleman disease (HHV-8-associated MCD), and 1000 are HHV-8-negative MCD. Moreover, The Castleman Disease Collaborative Network (CDCN) has teamed up with the University of Pennsylvania and the University of Arkansas for Medical Sciences to conduct a study of sirolimus, an investigational medicine, for adults with idiopathic multicentric Castleman disease (iMCD) who have failed to respond to anti-IL-6 therapies. Siltuximab (Sylvant) and tocilizumab are two anti-IL-6 drugs (Actemra). Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Major key players in the castleman disease treatment market are EUSA Pharma, Johnson & Johnson Services, Inc., Genentech USA, Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Bristol-Myers Squibb Company, Par Pharmaceutical, Exela Pharma Sciences.
EUSA Pharma was founded in March 2006. It is a newly-established, profitable specialty pharmaceutical company with global reach from its UK headquarters and commercial operations across Europe and the USA. It is focused on oncology and rare disease, continuously striving to confront gaps in patient care. EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America. It makes products available in approximately 40 countries worldwide through this broad international platform.
SYLVANT (siltuximab): It is the first and only FDA/EMA approved therapy for idiopathic Multicentric Castleman Disease (iMCD) and is recommended as the preferred first line therapy by clinical guidelines.
Visualize the composition of the castleman disease treatment market segmentation by type, diagnosis, treatment, end user, distribution channel, and region highlighting the key commercial assets and players.
Identify commercial opportunities in castleman disease treatment market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of castleman disease treatment market- level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The global castleman disease treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Research Professionals
Emerging Companies
Manufacturers
LIST NOT EXHAUSTIVE